Clinical TrialAug 10, 2026, 10:39 AM
NeOnc Technologies to Unveil Topline Phase 2a Results for NEO100
AI Summary
NeOnc Technologies is set to announce topline Phase 2a results for its investigational treatment NEO100 on August 12, 2026. This significant clinical readout for recurrent IDH1-mutant high-grade glioma is considered a major near-term catalyst, with the company having secured Orphan Drug, Fast Track, and Rare Pediatric Disease designations for NEO100. The announcement follows substantial insider buying, with the CEO investing over $500,000, and increasing institutional ownership, alongside international expansion with a new IND authorization in Abu Dhabi.
Key Highlights
- NeOnc Technologies to unveil topline Phase 2a results for NEO100 on August 12, 2026.
- The study evaluates intranasal NEO100 in patients with recurrent IDH1-mutant high-grade glioma.
- NEO100 holds Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA.
- Chairman, President, and CEO Amir Heshmatpour invested over $500,000 in open-market purchases.
- Insider buying has approached $1 million over the past year.
- Institutions including Bank of America, State Street, Barclays, and BlackRock are shareholders.
- Received a second Investigational New Drug (IND) authorization from Department of Health – Abu Dhabi.
- Investor conference call scheduled for August 12, 2026, at 8:30 a.m. Eastern Time.
Price Impact
More from NTHI